Opinion & analysis

Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation

Leading pharmaceutical executives called to testify before a Senate Finance Committee hearing on drug prices were likely the first of many to be summoned. It’s a no-win situation, but preparation can help. Find out why changing the subject can be a smart tactic. Discover how some senators may try to lure execs into inadvertently lying–and learn how to avoid it.

Big Pharma CEOs Get Ready To Testify: Preparing For A No-Win Situation

Biogen CMO Notes iPhone’s Potential For Early Detection of Alzheimer’s

BioMarin Is Carrying The Biggest Target On Its Back, Morningstar Says

Biosimilar Suffixes Appear Superfluous In Adverse Event Reporting

Biotech CEOs: Can Scientist-Founders Remain In Charge?

Breakthrough Designation Rescissions: Who Might US FDA Drop Next?

Brexit At The 11th Hour: UK Refreshes No-Deal Guidance For Medtech

Bristol-Myers, Celgene and The Perils Of The US Drug Pricing Environment

BSI Is Designated In Netherlands, Giving Clients Go-Ahead To Start Transfer Of Certificates

BSI Touts ‘Very Short’ Waiting Times For Migrating Certificates From UK To Netherlands

Burt’s Bees Hopes Third Time’s A Charm For Toothpaste, This One With P&G

Bye-Bye QSR? FDA May Swap Its Quality System Regulation For ISO 13485 ‘In The Coming Years,’ Official Says

Can Novartis Reclaim Pioneering Role In Transplantation?

Cancer Drug Combination Pricing: Genentech Offers Model For Tecentriq, Avastin

Cancer’s New Patient Demographic; Will Survivorship Change The Face Of Cancer Care?